Holen Sie sich die Stockscreener-App
48.77
0.87%
-0.43
Handel nachbörslich:
48.73
-0.04
-0.08%
Schlusskurs vom Vortag:
$49.20
Offen:
$49.07
24-Stunden-Volumen:
3.49M
Relative Volume:
0.32
Marktkapitalisierung:
$19.34B
Einnahmen:
$1.94B
Nettoeinkommen (Verlust:
$-2.82B
KGV:
-6.7161
EPS:
-7.2617
Netto-Cashflow:
$-2.08B
1W Leistung:
+1.12%
1M Leistung:
-7.14%
6M Leistung:
+77.09%
1J Leistung:
+94.23%
1-Tages-Spanne:
$48.20
$49.80
1-Wochen-Bereich:
$47.96
$52.78
52-Wochen-Spanne:
$22.28
$59.55
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
48.77 | 19.51B | 1.94B | -2.82B | -2.08B | -7.2617 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-12 | Eingeleitet | Jefferies | Hold |
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo Finance UK
Moderna: Speculative Buy For Aggressive Investors Betting On mRNA's Future (NASDAQ:MRNA) - Seeking Alpha
Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes - Insider Monkey
Is Moderna (MRNA) Pricing Make Sense After A 96% One Year Share Price Jump - Yahoo Finance
Top Moderna Shareholders - Investopedia
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
Moderna (MRNA) stock dips while market gains: Key facts - MSN
Moderna says the FDA will consider its new flu shot after resolving a public dispute - Dayton Daily News
Moderna (MRNA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Moderna (NASDAQ:MRNA) Target Update Sparks Nasdaq 100 Index Focus - Kalkine Media
Barclays Analyst Raises Price Target for Moderna (MRNA) to $48.0 - GuruFocus
Moderna (NASDAQ:MRNA) Price Target Raised to $48.00 at Barclays - MarketBeat
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment - BioSpace
Moderna, Inc. (NASDAQ:MRNA) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Moderna, Inc. Trade Ideas — BSESOF:0QF - TradingView
What's Going On With Pfizer Stock Wednesday?BioNTech (NASDAQ:BNTX), Pfizer (NYSE:PFE) - Benzinga
Moderna, Inc. Trade Ideas — EUROTLX:4MRNA - TradingView
Barclays Adjusts Price Target on Moderna to $48 From $25, Maintains Equalweight Rating - marketscreener.com
Moderna (MRNA) Valuation Check As Patent Dispute Settlement And Cancer Therapy Pivot Refocus Investor Attention - Yahoo Finance
Moderna, Pfizer Want Bayer's COVID-Shot Patent Suits Tossed - Law360
Moderna (MRNA) Experiences Bearish Sentiment Among Option Traders - GuruFocus
Oil Tumbles, Nasdaq 100 Jumps 3% As Iran Says It's Ready To Halt Hostilities: 10 Stocks Moving - Benzinga
Moderna, Pfizer Press to Toss Bayer’s Covid-Shot Patent Suits - Bloomberg Law News
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability - FinancialContent
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - dnj.com
Moderna, Inc. (MRNA) Stock Forecasts - Yahoo Finance
3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next - 24/7 Wall St.
Moderna's Spikevax Vaccine: Current Market Position, Strategic Developments and Investor Relevance i - AD HOC NEWS
EMA panel recommendation for mCOMBRIAX approval sees Moderna stock fall 7.49% - Traders Union
MRNA Stock Quote Price and Forecast - CNN
Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Moderna shares slide as investors weigh recent legal-cost clarity against fresh regulatory uncertainty - Quiver Quantitative
Stock Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - marketbeat.com
How (MRNA) Movements Inform Risk Allocation Models - Stock Traders Daily
ETFs Investing in Moderna, Inc. Stocks - TradingView
Azenta, 10x Genomics, PacBio, Oscar Health, and Moderna Shares Plummet, What You Need To Know - Yahoo Finance
What is behind Moderna stock's recent drop in value today - Traders Union
Vanguard realignment: Vanguard reports 0 MRNA shares (MRNA) - stocktitan.net
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? - TradingView
Moderna Inc. stock: mRNA pioneer's strategic pivot amid biotech sector challenges and vaccine market - AD HOC NEWS
Moderna Stock is Soaring. Is It Too Late to Buy? - The Globe and Mail
Metagenomi Can’t Ax IPO Investor Suit Over Moderna Partnership - Bloomberg Law News
What is behind Moderna stock's recent gain in value today - tradersunion.com
Moderna stands as the best performing large-cap healthcare stock YTD (XLV:NYSEARCA) - Seeking Alpha
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - Palm Beach Daily News
Moderna, Heidrick & Struggles Execs Talk AI Execution - WSJ
Moderna Inc. stock faces analyst pressure amid patent settlement with Arbutus Biopharma - ad-hoc-news.de
Moderna's Spikevax Vaccine: Current Status and Future Prospects in mRNA Technology Evolution - AD HOC NEWS
Lobbying Update: $100,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
Moderna Case Highlights Overlooked Hurdle In Biopharma IP - Law360
Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Moderna Inc-Aktie (MRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | Chief Legal Officer |
Mar 02 '26 |
Sale |
52.29 |
13,885 |
726,047 |
59,689 |
1.59%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):